Deals & Capital Markets
Merck Emerges as Lead Suitor for Revolution Medicines at $28-32 Billion
Jan 9
You're signed outSign in or to get full access.
Merck & Co. (MRK) Earnings Call Transcripts
Browse quarterly earnings call transcripts for Merck & Co..
